Last updated: September 24, 2026
Avatrombopag maleate, marketed as Doptelet, is an oral thrombopoietin receptor agonist commercialized by Swedish Orphan Biovitrum AB, or Sobi. Its strongest commercial position is in chronic liver disease patients with thrombocytopenia who require an invasive procedure. The drug also competes in immune thrombocytopenia, where it faces established therapies including eltrombopag, romiplostim, fostamatinib, and platelet transfusion.
Doptelet revenue has expanded since its U.S. launch through broader physician adoption, international rollout, and increased use in peri-procedural thrombocytopenia. Its market risk is concentrated in eventual generic entry, reimbursement pressure, and competition from other oral and injectable platelet-raising therapies. Because avatrombopag is a small molecule, biosimilar competition is not applicable.
What is avatrombopag maleate and how is Doptelet used?
Avatrombopag maleate is the maleate salt of avatrombopag, an orally administered thrombopoietin receptor agonist. It stimulates megakaryocyte proliferation and platelet production through the thrombopoietin receptor pathway.
The U.S. Food and Drug Administration approved Doptelet in 2018 for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure. FDA expanded the label in 2019 to include adults with chronic immune thrombocytopenia who had an insufficient response to a prior treatment.[1]
| Attribute |
Details |
| Active ingredient |
Avatrombopag maleate |
| Brand |
Doptelet |
| Developer |
Dova Pharmaceuticals |
| Current commercial owner |
Sobi |
| Drug class |
Oral thrombopoietin receptor agonist |
| U.S. approval |
May 2018 |
| U.S. ITP approval |
June 2019 |
| Main dosage forms |
20 mg tablets |
| Primary commercial uses |
Chronic liver disease thrombocytopenia; chronic immune thrombocytopenia |
| Administration |
With food |
| Biosimilar pathway |
Not applicable |
For chronic liver disease, treatment is generally administered for five consecutive days before a scheduled procedure. The dose depends on the patient’s baseline platelet count. For chronic immune thrombocytopenia, the drug is administered on a continuing basis with dose adjustment based on platelet response and safety.
What is the FDA regulatory status of avatrombopag?
Doptelet has full FDA approval for two indications and is not an accelerated-approval product. The regulatory profile is commercially favorable because the chronic liver disease indication addresses a defined procedural need and can reduce reliance on platelet transfusion or other rescue measures.
FDA approval timeline
| Date |
Regulatory event |
| May 2018 |
FDA approved Doptelet for adults with chronic liver disease thrombocytopenia scheduled for a procedure |
| June 2019 |
FDA approved Doptelet for adults with chronic immune thrombocytopenia after insufficient response to prior treatment |
| 2019 onward |
Sobi and regional partners expanded commercialization outside the United States |
The clinical evidence for the chronic liver disease indication included the ADAPT-1 and ADAPT-2 phase 3 trials. The studies evaluated the ability of avatrombopag to raise platelet counts sufficiently to avoid platelet transfusion or rescue therapy before an invasive procedure.[2]
The ITP indication was supported by a randomized phase 3 study and earlier clinical data showing platelet responses in patients who had received previous ITP therapies.[3]
How large is the avatrombopag market?
The addressable market has two distinct segments:
- Peri-procedural thrombocytopenia in chronic liver disease.
- Chronic immune thrombocytopenia requiring long-term platelet support.
The chronic liver disease market is more differentiated. Patients are treated for a short course before a procedure, which limits cumulative drug exposure and reduces some adherence concerns. The ITP market is larger in treatment duration but more competitive because physicians can choose among multiple established therapies.
Key commercial market drivers
- Growth in diagnosed chronic liver disease and cirrhosis.
- Greater use of invasive procedures in patients with liver disease.
- Avoidance of platelet transfusions and associated logistics.
- Oral administration compared with injectable romiplostim.
- Expansion of hematology prescribing in chronic ITP.
- Use after inadequate response to corticosteroids, intravenous immunoglobulin, rituximab, or other treatments.
- International reimbursement approvals and guideline inclusion.
Principal market constraints
- Avatrombopag is not a universal first-line treatment for ITP.
- The drug requires administration with food, which can create adherence and administration complexity.
- Thrombotic and thromboembolic events remain relevant safety considerations in patients with chronic liver disease.
- Chronic ITP patients can switch among several thrombopoietin receptor agonists.
- Generic substitution could materially reduce net pricing after relevant patents expire.
What has been the financial trajectory of Doptelet?
Doptelet has been one of Sobi’s important growth products since the company acquired Dova Pharmaceuticals. Sobi agreed to acquire Dova in 2019 in a transaction valued at approximately $915 million, including assumed debt and other transaction components.[4] The acquisition gave Sobi control of a commercial-stage product with a U.S. hematology franchise and international expansion potential.
Public Sobi reporting indicates that Doptelet revenue increased substantially from the early post-acquisition period through 2023. The following figures are rounded estimates derived from Sobi annual reports and reported product commentary.
| Fiscal year |
Approximate Doptelet revenue |
Commercial context |
| 2019 |
About SEK 0.4 billion |
Dova-led U.S. commercialization |
| 2020 |
About SEK 1.1 billion |
Sobi ownership and broader commercial infrastructure |
| 2021 |
About SEK 1.6 billion |
Continued U.S. growth and international expansion |
| 2022 |
About SEK 2.1 billion |
Increased use in liver disease and ITP |
| 2023 |
About SEK 2.6 billion |
Continued double-digit growth and geographic expansion |
The revenue trajectory reflects both volume growth and geographic expansion. It does not represent a pure price-growth story. Doptelet’s early revenue base was concentrated in the United States, while later growth included additional European and international markets.
Sobi’s acquisition economics were based on continued label expansion, higher prescriber penetration, and the expected durability of the product’s patent and regulatory position. The investment case depends on maintaining growth before generic competition becomes commercially viable.
How does avatrombopag compare with competing thrombocytopenia drugs?
Avatrombopag competes with both oral and injectable platelet-raising products. Its most direct competitors differ by indication.
| Product |
Active ingredient |
Company |
Administration |
Main competitive position |
| Doptelet |
Avatrombopag |
Sobi |
Oral |
Peri-procedural CLD thrombocytopenia and chronic ITP |
| Mulpleta |
Lusutrombopag |
Shionogi |
Oral |
Peri-procedural CLD thrombocytopenia |
| Promacta/Revolade |
Eltrombopag |
Novartis |
Oral |
Chronic ITP, severe aplastic anemia, selected hepatitis-related use |
| Nplate |
Romiplostim |
Amgen |
Subcutaneous injection |
Chronic ITP |
| Tavalisse |
Fostamatinib |
Rigel Therapeutics |
Oral |
Chronic ITP after prior treatment failure |
| Platelet transfusion |
Donor platelets |
Blood-service providers |
Intravenous |
Acute procedural support and rescue treatment |
Avatrombopag versus lusutrombopag
Lusutrombopag is the closest competitor in the chronic liver disease procedural market. Both products are oral thrombopoietin receptor agonists administered before an invasive procedure. Competitive factors include:
- Baseline platelet thresholds.
- Number of treatment days.
- Ability to avoid platelet transfusion.
- Hospital and procedural workflow.
- Contracting and reimbursement.
- Physician familiarity.
- Local regulatory labeling.
Doptelet has a broader commercial profile because it also has an FDA-approved chronic ITP indication. Mulpleta is more concentrated in peri-procedural thrombocytopenia.
Avatrombopag versus eltrombopag
Eltrombopag has a longer commercial history, broader physician familiarity, and a large installed base in ITP and aplastic anemia. Avatrombopag can differentiate through its dosing profile and the absence of some food and mineral restrictions associated with eltrombopag. Eltrombopag’s longer market history also gives it greater generic and pricing exposure in certain markets.
Avatrombopag versus romiplostim
Romiplostim is injectable and typically administered weekly. Doptelet’s oral route can support home treatment and reduce injection burden. Romiplostim remains competitive where physicians prioritize established long-term experience or where injection-based clinic administration supports adherence.
What patents protect avatrombopag and Doptelet?
Doptelet is protected by a combination of compound, formulation, pharmaceutical-composition, and method-of-use rights. The patent estate originated with the avatrombopag development program and was associated with Dova’s commercialization rights.
Patent protection categories
- Avatrombopag compound patents.
- Salt and pharmaceutical-composition patents.
- Tablet and formulation patents.
- Methods for increasing platelet counts.
- Treatment of thrombocytopenia associated with chronic liver disease.
- Treatment of chronic immune thrombocytopenia.
- Peri-procedural dosing methods.
The U.S. Orange Book is the controlling source for listed patents and regulatory exclusivity. Patent expiration dates can vary by patent family, terminal disclaimers, patent-term adjustment, pediatric extensions, and litigation outcomes.[5]
For commercial purposes, the relevant protection is not a single expiration date. The risk window depends on whether a generic applicant can challenge each listed patent through Paragraph IV certification or can wait for expiration of the relevant method and formulation claims.
When does avatrombopag lose exclusivity?
Doptelet’s principal U.S. market exclusivity periods have already expired or are no longer the main barrier to generic entry. The continuing protection is primarily patent-based.
The FDA granted Doptelet orphan-drug exclusivity for the chronic liver disease indication. That exclusivity protected the approved indication for seven years from approval, subject to the statutory orphan-drug framework. The ITP indication received separate regulatory protection associated with its 2019 approval.[1]
The practical generic-entry date depends on:
- The final unexpired Orange Book patent.
- Whether a generic applicant files a Paragraph IV certification.
- Whether Sobi brings patent litigation within the statutory period.
- Whether the patents cover the generic’s proposed label.
- Whether the applicant uses a different formulation or dosage design.
- Any settlement agreement between Sobi and a generic manufacturer.
Are there Paragraph IV challenges to avatrombopag?
A Paragraph IV challenge would allow a generic applicant to certify that a listed Doptelet patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation and, in many cases, a 30-month stay of FDA approval under the Hatch-Waxman framework.[6]
Public commercial information through 2024 does not show a generic avatrombopag product launched in the United States. The absence of a marketed generic does not eliminate future Paragraph IV risk. Generic applicants may wait for a strategically favorable patent window, particularly if the remaining claims cover chronic ITP methods, peri-procedural dosing, or the commercial tablet formulation.
Generic launch scenarios
| Scenario |
Likely commercial impact |
| No challenge before key patent expiration |
Sobi retains branded sales until generic approval |
| Paragraph IV litigation with settlement |
Entry date depends on settlement terms |
| Early successful invalidity challenge |
Rapid erosion in U.S. sales and net price |
| Non-infringing formulation approval |
Partial market entry and narrower substitution |
| Multiple generic approvals |
Accelerated price erosion and payer substitution |
Method-of-use patents can delay direct substitution if the generic label omits a protected indication. That strategy is less effective when physicians prescribe the generic for overlapping platelet disorders or when pharmacy substitution rules allow broad use.
Is there biosimilar risk for avatrombopag?
There is no biosimilar risk because avatrombopag is a chemically synthesized small molecule, not a biologic. The relevant threat is conventional generic competition under the Abbreviated New Drug Application pathway.
Generic manufacturers would generally need to demonstrate pharmaceutical equivalence and bioequivalence rather than reproduce a biologic manufacturing process. This makes manufacturing entry less technically difficult than entry for a monoclonal antibody or recombinant protein.
How strong is the avatrombopag patent estate?
The patent estate is commercially meaningful but not structurally comparable to a complex biologic or device combination product.
Strengths
- FDA approval in two indications.
- Differentiated peri-procedural use.
- Multiple potential claim categories.
- Established commercial demand.
- Clinical data supporting a defined treatment population.
- Manufacturing know-how and regulatory history.
Weaknesses
- Small-molecule chemistry is generally accessible to generic manufacturers.
- The active ingredient is not protected by biologic complexity.
- Method-of-use claims may be vulnerable to label carve-outs.
- Chronic ITP has strong therapeutic competition.
- Formulation claims may be designed around.
- Short-course procedural dosing can be easier to replicate than a complex delivery system.
The estate is strongest where claims cover the specific avatrombopag compound, approved dosage form, and commercially important dosing regimens. It is weaker where protection depends only on broad treatment concepts or indications that a generic applicant can omit from its label.
What licensing deals and ownership changes affect avatrombopag?
Dova Pharmaceuticals developed and commercialized avatrombopag before Sobi acquired the company. Sobi announced the Dova acquisition in September 2019 and completed the transaction later that year.[4]
The deal transferred control of Doptelet and related commercial rights to Sobi. It also shifted the product from a single-product biotechnology commercial model to a larger specialty-pharmaceutical platform. Sobi’s infrastructure supported broader international distribution, market access, medical affairs, and lifecycle management.
The transaction remains central to the product’s financial trajectory because the acquisition price created a substantial return requirement. Continued revenue growth and patent durability are necessary to support the transaction’s valuation.
What litigation and settlement risks affect Doptelet?
The principal legal risks are likely to arise from Hatch-Waxman litigation, Orange Book patent challenges, and disputes over patent-listing scope. Litigation risk increases as Doptelet sales grow and the commercial value of U.S. generic entry rises.
Key issues could include:
- Validity of compound or formulation claims.
- Obviousness of avatrombopag salts or dosage forms.
- Written-description and enablement issues.
- Infringement by generic tablet formulations.
- Label-scarving strategies for method-of-use patents.
- Patent-term calculations.
- Settlement timing and permitted generic entry date.
No publicly established settlement date should be treated as the expected generic launch date unless it is disclosed in court filings, an SEC filing, or an FDA-related record.
What is the financial exposure to Sobi?
Doptelet is material to Sobi’s growth portfolio but is not the company’s only major product. Sobi also commercializes therapies in hematology, immunology, and rare diseases. A generic launch would therefore affect product-level growth, gross margin, and portfolio mix rather than eliminate the company’s revenue base.
The financial impact would likely follow a staged pattern:
- Continued branded growth while no generic is approved.
- Price concessions and increased rebates after an ANDA approval.
- Rapid volume migration in pharmacy-controlled channels.
- Slower erosion in physician-administered or specialty channels.
- Residual branded demand for patients stabilized on Doptelet or covered under specific payer arrangements.
The chronic liver disease procedural market may experience slower substitution than chronic maintenance ITP because treatment is episodic and tied to institutional protocols. Chronic ITP could experience faster substitution if payers establish generic-first policies.
What is the outlook for avatrombopag maleate?
Doptelet’s near-term outlook is supported by its two-indication label, oral administration, and established use in procedural thrombocytopenia. Revenue can continue to expand through international penetration and increased use in patients with chronic liver disease.
The medium- to long-term outlook is more exposed to generic entry. The product’s small-molecule structure makes eventual ANDA competition likely once the relevant patent barriers are removed. Sobi’s commercial priorities are therefore likely to include maintaining prescriber loyalty, defending reimbursement, expanding geographic access, and managing the product’s lifecycle before the principal patent cliff.
Key Takeaways
- Avatrombopag maleate is marketed as Doptelet by Sobi.
- FDA approvals cover chronic liver disease thrombocytopenia before procedures and chronic immune thrombocytopenia.
- The strongest differentiation is in short-course peri-procedural treatment.
- Doptelet revenue increased from roughly SEK 0.4 billion in 2019 to approximately SEK 2.6 billion in 2023.
- The closest product competitor in chronic liver disease is lusutrombopag.
- Eltrombopag and romiplostim remain major competitors in chronic ITP.
- Biosimilar competition does not apply; the relevant threat is generic avatrombopag.
- Generic timing depends on Orange Book patents, Paragraph IV filings, litigation, and any settlement agreement.
- The patent estate has commercial value but faces the normal design-around and label-carve-out risks associated with small-molecule products.
- Sobi’s Dova acquisition created substantial dependence on sustained Doptelet growth and patent durability.
FAQs
Does avatrombopag require platelet transfusion before surgery?
Doptelet is intended to raise platelet counts before a scheduled procedure and can reduce the need for platelet transfusion or rescue treatment. It does not eliminate transfusion requirements for every patient.
Is Doptelet safer than eltrombopag?
The products have different safety, dosing, food, and drug-interaction profiles. Treatment selection depends on platelet response, liver disease status, thrombotic risk, prior therapy, and the approved indication.
Can avatrombopag be used for chemotherapy-induced thrombocytopenia?
FDA approval for Doptelet does not broadly cover chemotherapy-induced thrombocytopenia. Use outside the approved label depends on physician judgment and applicable local requirements.
What is the difference between avatrombopag and lusutrombopag?
Both are oral thrombopoietin receptor agonists used before procedures in patients with chronic liver disease and thrombocytopenia. Their dosing schedules, labels, clinical-trial populations, reimbursement, and commercial availability differ by jurisdiction.
Will generic avatrombopag be automatically substituted for Doptelet?
Automatic substitution depends on FDA approval, state pharmacy law, payer policy, formulation equivalence, and the approved generic label. Approval of a generic does not guarantee immediate substitution across all channels.
References
-
U.S. Food and Drug Administration. (2018). Doptelet (avatrombopag maleate) prescribing information. FDA.
-
Terrault, N., Chen, Y.-C., Izumi, N., Kayali, Z., Mitrut, P., Tak, W.-Y., Jang, J. Y., et al. (2018). Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology, 155(3), 705-718.
-
Jurczak, W., Chojnowski, K., Mayer, J., Kloczko, J., Usenko, A., Salama, A., Ghanima, W., et al. (2018). Phase 3 randomised study of avatrombopag, an investigational thrombopoietin receptor agonist, in adult patients with chronic immune thrombocytopenia. British Journal of Haematology, 183(3), 479-490.
-
Swedish Orphan Biovitrum AB. (2019). Sobi to acquire Dova Pharmaceuticals. Stockholm: Sobi.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
